In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mandy Jackson

Mandy Jackson is the US West Coast Editor for Scrip Intelligence. Mandy reports on daily biopharma news and regularly interviews everyone from big pharma CEOs to biotech startup founders about the business strategy behind their finance, dealmaking and drug development news. She also has an interest in drug pricing and novel reimbursement strategies, new treatments in areas of true unmet need, and business development trends. Mandy has been a business news reporter for more than 15 years, covering biotech and pharma companies, biotech law and commercial real estate. She is based in San Diego, California – the venue for many medical and biopharma industry meetings.

Latest From Mandy Jackson

The Next Big Thing In Gene Therapy Might Not Be Gene Therapy

Gene therapy remains attractive when data show new technologies can advance the field, but gene regulation, editing and RNA therapies are grabbing investors’ attention, panelists said at ARM’s Cell and Gene Meeting on the Mesa.

Gene Therapy Financing

US Vs. EU: Is Cell And Gene Therapy Reimbursement Easier Stateside?

A bluebird executive spoke during ARM’s Cell and Gene Meeting On The Mesa about why the firm pulled Zynteglo out of the EU, but while progress has been made in the US, long-term challenges remain.

Gene Therapy Market Access

Finance Watch: Three Newly Public Companies Face Mixed Reception In Early Trading

Also, two more health care-focused SPACs went public, Centessa obtained up to $300m in debt, three new venture capital funds launched and Intergalactic debuted with a $75m series A round.

Financing Business Strategies

Neumora Launches With $500m To Advance Personalized Neuroscience Drugs

Combining biological insights with data science, the start-up emerges from stealth mode after two years of assembling its technology platform and R&D pipeline based on internal and external know-how.

Financing StartUps and SMEs

Takeda Halts Phase II Studies For Key R&D Asset TAK-994 In Narcolepsy

The company stopped Phase II clinical trials for TAK-994 to assess a safety signal and determine next steps for the drug, which is viewed as a key product in Takeda’s push for blockbuster revenue growth. 

Clinical Trials Drug Safety

Biohaven’s Q3 Nurtec ODT Sales Indicate Gains Across Multiple Launch Parameters

The company pre-announced $136m in third quarter sales, beating analyst consensus and signaling both increased oral CGRP inhibitor market share and improved per-prescription net revenue.

Launches Sales & Earnings
See All
UsernamePublicRestriction

Register